-100%

est. 2Y upside i

HealthcareIPO

Rank

#3790

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: Low

Do not join OvaScience.

Last updated: July 21, 2026

Bull (10%)-100%

No realistic bull scenario; company is failing with no product traction and high cash burn.

Base (40%)-100%

Base case assumes continued decline; no path to profitability or exit.

Bear (50%)-100%

Bear case: company runs out of cash, common stock worthless.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

15630%

Total funding of $76.9M exceeds current valuation of $49.2M, meaning preferred stock has full preference and common stock gets nothing in most exits.

Dilution Risk

high

Given the company's weak position, further dilutive financing is likely if they attempt to continue, but current data suggests imminent failure.

Secondary Liquidity

none

No secondary market activity reported.

Questions to Ask at the Interview

Strategic questions based on OvaScience's data — designed to show you've done your homework.

  • 1

    “What is the company's runway based on current cash burn?”

  • 2

    “How do you see the Augment treatment differentiating from standard IVF?”

  • 3

    “With the reverse merger, what is the equity structure for common shareholders?”

Community

Valuation Sentiment

Our model estimates -100% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.